Cathie Wood's ARK Invest bought Recursion Pharmaceuticals and CRISPR Therapeutics while selling PagerDuty, Teradyne, and Salesforce on8, 2026.

Major investors Nvidia and Novo Holdings A/S have fully exited their positions in Recursion Pharmaceuticals (NasdaqGS:RXRX), signaling a shift in institutional backing. Recursion has acquired full ...

In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.53, indicating a +2.02% shift from the previous trading day.

In the biotech sphere, ARK continued its accumulation of CRISPR Therapeutics AG (NASDAQ:CRSP) by acquiring 37,075 shares worth $1.97 million. This purchase is part of a broader strategy, as ARK has ...

Nvidia disclosed in a filing on Tuesday that it no longer held shares in Applied Digital, drug-discovery company Recursion ...

Recursion Pharmaceuticals Inc RXRX shares are under pressure Wednesday after new regulatory filings showed that Nvidia Corp NVDA has fully exited its investment in the AI‑focused drug‑discovery ...

Nvidia updated its stock portfolio with a $9 billion boost, shifting focus to Intel, Synopsys, and Nokia in Q3 and Q4 of 2025.

Applied Digital shares dropped after Nvidia said it had sold its position in the AI infrastructure provider, as well as its ...

Company to host public (L)earnings call on February 25 at 8:00 am ET / 6:00 am MT / 1:00 pm GMTSalt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage ...

NVIDIA’s most recent 13F filing showed no position in Recursion Pharmaceuticals, indicating a complete exit from its previous holding of 7.71 million shares. The semiconductor giant had maintained its ...

Earnings ESP of RXRX: Recursion Pharmaceuticals has an Earnings ESP of 0.00% as the Most Accurate Estimate and the Zacks ...

Dr. James McCaffrey presents a complete end-to-end demonstration of decision tree regression from scratch using the C# language. The goal of decision tree regression is to predict a single numeric ...